{"nctId":"NCT02870205","briefTitle":"Efficacy and Safety of GSP 301 Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (SAR)","startDateStruct":{"date":"2016-08","type":"ACTUAL"},"conditions":["Seasonal Allergic Rhinitis (SAR)"],"count":1176,"armGroups":[{"label":"GSP 301 NS","type":"EXPERIMENTAL","interventionNames":["Drug: GSP 301 NS"]},{"label":"GOM-NS","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: GOM-NS"]},{"label":"GMM-2 NS","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: GMM-2 NS"]},{"label":"GSP 301 placebo NS","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: GSP 301 placebo NS"]}],"interventions":[{"name":"GSP 301 NS","otherNames":[]},{"name":"GOM-NS","otherNames":[]},{"name":"GMM-2 NS","otherNames":[]},{"name":"GSP 301 placebo NS","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Males and non-pregnant females who are 12 years of age and older.\n* Documented clinical history of SAR (for at least 2 years preceding the Screening Visit \\[Visit 1\\]) with exacerbations (clinical evidence of active symptoms) for the relevant seasonal allergen during the Fall or mountain cedar allergy seasons (e.g., ragweed or mountain cedar pollen)\n* A 12-hour rTNSS ≥8 out of a possible 12 and a congestion score ≥2 for the AM assessment at the Screening Visit (Visit 1).\n\nExclusion Criteria:\n\n* Pregnant or lactating women.\n* History of anaphylaxis and/or other severe local reaction(s) to skin testing.\n* History of positive test for HIV, Hepatitis B or Hepatitis C infection.\n* Documented evidence of acute or significant chronic sinusitis or chronic purulent postnasal drip.\n* Subjects with an active pulmonary disorder or infection.\n* Subjects with posterior subcapsular cataracts or glaucoma\n* Plans to travel outside the known pollen area for the investigational site for 24 hours or longer during the last 7 days of the run-in period.","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Average AM and PM Subject-reported 12-hour Reflective Total Nasal Symptom Score (rTNSS)","description":"The Reflective Total Nasal Symptom Score (rTNSS) was assessed by 12-hour reflective scoring of the severity of four nasal symptoms (rhinorrhea, sneezing, nasal congestion, nasal itching). Symptom scores ranged from 0 (no signs/symptoms evident) to 3 (severe signs/symptoms that is hard to tolerate). The rTNSS was calculated as the sum of the subject-reported severity scores for nasal symptoms, and value ranged from 0 (no signs/symptoms evident) to 12 (severe signs/symptoms that is hard to tolerate).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.3","spread":"1.2"},{"groupId":"OG001","value":"10.1","spread":"1.2"},{"groupId":"OG002","value":"10.2","spread":"1.3"},{"groupId":"OG003","value":"10.2","spread":"1.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.9","spread":"3.2"},{"groupId":"OG001","value":"-4.3","spread":"3.1"},{"groupId":"OG002","value":"-3.6","spread":"3.3"},{"groupId":"OG003","value":"-3.5","spread":"3.5"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":294},"commonTop":[]}}}